Select Page

Anti-Human CD194 (CCR4) (Mogamulizumab) – HRP – 100 µg

100 μg



ApplicationDepletion, ELISA, FA, FC
ConjugateHorseradish Peroxidase (HRPO)
IsotypeHuman IgG1κ
ImmunogenHumanization of mouse anti-CCR4 mAb7.
Species ReactivityHuman
FormulationThis HRP-conjugated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4, 1% BSA. (Warning: Use of sodium azide as a preservative will inhibit the enzyme activity of horseradish peroxidase)
Research AreaCancer, Immunology
Description/BackgroundClone KW-0761 (Mogamulizumab) is a research-grade, afucosylated, humanized monoclonal antibody generated from mouse anti-CCR4 mAb7 that targets human CCR4.1 CC chemokine receptor type 4 (CCR4) is a protein that belongs to the G protein-coupled receptor family and is a receptor for a variety of CC chemokines including MCP-1, MIP-1, RANTES, TARC, and Macrophage-derived chemokine. Chemokines are involved in the development, homeostasis, and function of the immune system and are known to regulate cell trafficking of various types of leukocytes. In a 2018 Phase I clinical trial, Mogamulizumab was found to decrease the number of HTLV-1–infected cells and the levels of inflammatory markers related to HTLV-1–Associated Myelopathy.3
Storage TemperatureThis horseradish peroxidase conjugated monoclonal antibody is stable when stored at 2-8°C. Do not freeze.
ProtocolsDepletion, ELISA, FA, FC
Clone NumberKW-0761
Concentration0.5 mg/ml
Regulatory StatementFor Research Use Only. Not for use in diagnostic procedures.
100 μg